| Literature DB >> 26817483 |
Rainer H Straub1, Carsten Schradin2.
Abstract
It has been recognized that during chronic inflammatory systemic diseases (CIDs) maladaptations of the immune, nervous, endocrine and reproductive system occur. Maladaptation leads to disease sequelae in CIDs. The ultimate reason of disease sequelae in CIDs remained unclear because clinicians do not consider bodily energy trade-offs and evolutionary medicine. We review the evolution of physiological supersystems, fitness consequences of genes involved in CIDs during different life-history stages, environmental factors of CIDs, energy trade-offs during inflammatory episodes and the non-specificity of CIDs. Incorporating bodily energy regulation into evolutionary medicine builds a framework to better understand pathophysiology of CIDs by considering that genes and networks used are positively selected if they serve acute, highly energy-consuming inflammation. It is predicted that genes that protect energy stores are positively selected (as immune memory). This could explain why energy-demanding inflammatory episodes like infectious diseases must be terminated within 3-8 weeks to be adaptive, and otherwise become maladaptive. Considering energy regulation as an evolved adaptive trait explains why many known sequelae of different CIDs must be uniform. These are, e.g. sickness behavior/fatigue/depressive symptoms, sleep disturbance, anorexia, malnutrition, muscle wasting-cachexia, cachectic obesity, insulin resistance with hyperinsulinemia, dyslipidemia, alterations of steroid hormone axes, disturbances of the hypothalamic-pituitary-gonadal (HPG) axis, hypertension, bone loss and hypercoagulability. Considering evolved energy trade-offs helps us to understand how an energy imbalance can lead to the disease sequelae of CIDs. In the future, clinicians must translate this knowledge into early diagnosis and symptomatic treatment in CIDs.Entities:
Keywords: disease sequelae; energy regulation; inflammatory systemic disease; neuroendocrine immunology
Year: 2016 PMID: 26817483 PMCID: PMC4753361 DOI: 10.1093/emph/eow001
Source DB: PubMed Journal: Evol Med Public Health ISSN: 2050-6201
Risk factors of rheumatoid arthritis
| HLA system (HLA DR4 [DRB1*04]) |
| tumor necrosis factor alpha-induced protein 3 (TNFAIP3) (negative regulator of the NF-kappaB pathway) |
| protein tyrosine phosphatase receptor type C (CD45) (receptor and protein tyrosine phosphatase) |
| interferon gamma receptor 2 (cytokine receptor) |
| CD40 (cell surface molecule and receptor) |
| tyrosine kinase 2 (TYK2) (signaling of cytokine receptors) |
| IL-6 receptor (cytokine receptor) |
| protein tyrosine phosphatase type 22 (PTPN22) (signaling of receptors) |
| Fc-gamma receptor II 2B (CD32, Fc fragment of IgG, low affinity IIb receptor) |
| IL-2 (cytokine) |
| IL-2 receptor alpha chain (cytokine receptor) |
| SH2B3 (member of the SH2B adaptor family of proteins, signaling of growth factor and cytokine receptors) |
| ICOSLG (inducible T-cell co-stimulator ligand) |
The respective single nucleotide polymorphism in the mentioned genes have been found in genome-wide association studies [42]. The list is ordered according to the significance level of the statistical test for relative risk. HLA, human leukocyte antigen; IL, interleukin; TNF, tumor necrosis factor.
Concordance rate in twin studies in chronic inflammatory systemic diseases
| Disease | Monozygotic concordance rate (%) | Refs |
|---|---|---|
| Rheumatoid arthritis | 0–21 | [ |
| Hashimoto thyroiditis | 17 | [ |
| Systemic lupus erythematosus | 11–24 | [ |
| Multiple sclerosis | 6–31 | [ |
| Graves’ disease | 22 | [ |
| Type 1 diabetes mellitus | 13–38 | [ |
| Psoriasis | 35 | [ |
| Ankylosing spondylitis | 50 | [ |
Examples of antagonistic pleiotropy for genes that increase risk or severity of chronic inflammatory diseases [80]
| Genes | Chronic inflammatory disease | Pleiotropic meaning outside of chronic inflammatory diseases (with selection advantage) | Refs. |
|---|---|---|---|
| HLA DR4 (DRB1*04) | Rheumatoid arthritis and other autoimmune diseases | Decrease of risk of Dengue hemorrhagic fever (defense against infectious agents) | [ |
| Fc-gamma receptor IIIA, 158 valine/valine | Rheumatoid arthritis and other autoimmune diseases | Decrease of poliomyelitis infection due to strong natural killer cell activity (defense against infectious agents) | [ |
| HLA B27 | Ankylosing spondylitis and other axial forms of spondyloarthritis | Decrease of viral infection (defense against infectious agents) | [ |
| PTPN22 1858 C > T* | Many autoimmune diseases | Improved storage of energy-rich fuels (higher body mass index, higher waist-to-hip ratio in women) | [ |
| CTLA4 49 A > G | Many autoimmune diseases | Better defense against hepatitis B virus and helicobacter pylori (defense against infectious agents) | [ |
| NOD2/CARD15 | Crohn’s disease | Hypertension (activation of the sympathetic nervous system and, thus, the fight-and-flight response) | [ |
Figure 1.Incidence rate of rheumatoid arthritis (RA). The black line indicates the normal situation with a menopause starting at 45 years of age. The red line demonstrates a fictitious situation with accelerated menopause years before
Positively selected immune mechanisms under defined conditions of A) acute, highly energy-consuming responses terminated within 3–8 weeks and B) long-standing, energy-protective responses
| Positively selected for acute, highly energy-consuming situations | Positively selected to protect energy stores |
|---|---|
| Immune response due to infection | Tolerogenic immune reactions |
| Immune response to foreign bodies | Control of inner and outer body surfaces |
| Clonal expansion and apoptosis | Memory of the immune system |
| Wound healing, burn wounds | Replacement of cells and tissue (physio logical regeneration and degeneration) |
| Implantation of stems cells into injured tissue | Implantation of a blastocyst into the uterine epithelium |
| Specific immunoglobulin production and affinity maturation | Immune phenomena facilitating semiallogenic pregnancy |
| High production rate of cytokines and chemokines | Allergic reactions (preformed response to clear or block threats on body surfaces) |
| Increased rate of phagocytosis | |
| Immune stimulated neoangiogenesis and wound healing |
The list is not complete.
Common signs and symptoms in chronic inflammatory systemic diseases
| Overt symptoms | Change |
|---|---|
| Amenorrhea | Increases |
| Avolition | Increases |
| Body temperature and sweating | Increases |
| Bone loss | Increases |
| Cachexia, cachectic obesity | Increases |
| Circadian rhythms of symptoms | Become apparent |
| Coagulation system | Activated |
| Disposition to pain (skeletal muscle, joints, other) | Increases |
| Erythrocyte sedimentation rate | Increases |
| Fatigue | Increases |
| Food intake, appetite (finally body weight), malnutrition | Decreases |
| Headache | Increases |
| Heart rate, sympathetic nervous tone | Increases |
| Hemoglobin per erythrocyte, inflammation-related anemia | Decreases |
| Hypertension and volume expansion/water retention | More often |
| Insulin resistance | Increases |
| Interleukin-6 serum levels (one example of a cytokine in the blood) | Increases |
| Libido, erectile dysfunction (loss of activity of the HPG axis) | Decreases |
| Numbness | Increases |
| Parasympathetic tone | Decreases |
| Physical activity | Decreases |
| Proinflammatory high density lipoproteins (HDL), dyslipidemia | Increases |
| Protein in the urine | Increases |
| Serum albumin | Decreases |
| Sleeping problems | Increases |
| Stress negatively influences inflammation | Becomes apparent |
| Symptoms of depression | Increases |
| Vertigo | Increases |
| Weakness | Increases |
This list is not complete. HPG axis, hypothalamic-pituitary-gonadal axis.
Figure 2.There is a critical difference between typical inflammation and chronic inflammatory systemic diseases, which separates the asymptomatic phase from the symptomatic phase of a chronic inflammatory systemic disease, the asymptomatic-symptomatic-threshold (a-s-threshold). Importantly from an evolutionary point of view, reproduction is only impeded during the symptomatic, but not during the asymptomatic phase. Genes enabling an adaptive inflammatory response, allowing the organism to overcome an infection, will thus increase survival probability and the potential for future reproduction and as such evolutionary fitness in young age. After initiation of chronic systemic inflammation, however, reproduction is inhibited, and this for prolonged periods, often for years and until death, causing fitness costs. However, as these costs typically occur only at the end of the reproductive life-history stage or in post-reproductive age, these fitness costs are lower than the fitness benefits in early life leading to an overall increase in Darwinian fitness